Current Edition

Collaborative Drug Development for Rare Diseases

Patient groups are essential partners for clinical research as they are usually the most invested, and can therefore drive drug development. Often, patient groups focus on a single disease, and so are prepared to focus all of their time on understanding that disease and seeking solutions for its treatment. However, patient groups cannot work alone; they require the expertise of other partners. Oliver Timmis of the AKU Society and Anthony Hall of Findacure believe that a collaborative approach to drug development for rare diseases is the best way forward, and explore the 10 steps leading to clinical research in this article.